ANALYSIS OF RESEARCH ON THE BENEFITS OF CLINICAL AND ECONOMIC EFFECTIVENESS, SAFETY OF INNOVATIVE DRUG CETUXIMAB IN THE TREATMENT OF COLORECTAL CANCER

© E. Litvinova

Introduction

Statistics show that over the past 100 years, the oncopathology has moved from the tenth place to the second by the level of morbidity and mortality in the world, second only to diseases of the cardiovascular system. According to the WHO, every year 10 million people are ill again. According to WHO, cancer deaths by 2030 will increase by 45% compared to that in 2007 [1].

Formulation of the problem in a general way, the relevance of the theme and its connection with important scientific and practical issues

Oncopathology remains one of the most urgent and expensive non-communicable diseases that the health system faces. Celis et al. argue that the combination of innovative prevention and treatment strategies in the modern European cancer center will enable long-term survival of 3 out of 4 cancer patients by 2030 in countries with well-developed health systems [2].

Analysis of recent studies and publications in which a solution of the problem is described and to which the author refers

During the last decade, targeting therapy has dominated the oncology. Thus, in clinical practice, the treatment of solid and hematological malignant tumors is increasingly used anti-tumor monoclonal antibodies targeting specific antigens on the surface of cancer cells. The main advantages of such antibodies are a long half-life, low toxicity and high specificity [3].

Colorectal cancer (CRC) is one of the most common malignant neoplasms. Every year in the world more than 800 thousand new cases of CRC are registered, and the number of deaths exceeds half of new patients. Cetuximab is one of the antitumor monoclonal drugs for the treatment of CRC.

Along with the successes in healthcare, it should be noted that the cost of treatment for cancer has increased significantly in recent years and is projected to increase. The mentioned threatens the possibility of long-term access of patients to cancer care. In some cases, it has noted the minor advantages of new anticancer drugs, so an increase in life expectancy was 1.2–2.7 months [4]. Ferguson et al. note that there is no need to pay a premium for innovative medicines if they do not increase life expectancy for at least three months compared with existing standards [5]. Experts from the UK report similar timeframes (in terms of increasing survival) in assessing the significance of new drugs in the terminal stage of cancer [6]. The Cancer Research Committee of the American Cancer Society has identified an increase in the median of absolute survival in the range of 2.5–6 months for a number of tumors as a minimum indicator of additional benefit. It determines clinically meaningful results for a new cancer drug (depending on the type of tumor) [7]. In Germany, the (Institute
for Quality and Efficiency in Health Care-Home, IQWIG, an independent organization that assesses the quality and effectiveness of medical technologies and products) allocates 6 grades of availability/absence of additional therapeutic benefits: significant; moderate; minimal; additional clinical benefit is not subject to registration; lack of proven added efficiency; the benefit is less than that of the comparator [8].

4. The field of research considering the general problem, which is described in the article

In the literature it has discusses the high cost of new innovative drugs that exhibit similar efficacy in comparison with pharmaceuticals already available in the pharmaceutical market. In recent years, attention to this problem has increased significantly. The specified causes the necessity of further researches concerning an estimation of additional clinical usefulness of innovative drugs in comparison with existing preparations for treatment of oncolgical diseases.

5. Formulation of goals (tasks) of article

The aim of the work is to analyze and systematize literature data on the benefits of clinical and economic efficiency, safety of cetuximab in the treatment of colorectal cancer.

6. Presentation of the main research material (methods and objects) with the justification of the results

Studies were conducted using databases on the Internet: PubMed; Food and Drug Administration, European Medicines Agency. It has used retrospective, logical, statistical and system-analytical research methods.

In order to reduce the unpredictable increase in the cost of innovative drugs for the treatment of cancer, widespread use of comparative clinical efficacy studies is needed when discussing new therapies and identifying explicit benefits to drugs that are already being used in clinical practice. The systematic data on the significant clinical benefits of cetuximab, which have been studied in randomized trials, are given in Table 1.

The reported data indicate that cetuximab is an effective drug for the treatment of patients with metastatic CRC with wild-type RAS and expression of epidermal growth factor receptors EGFR, in combination with irinotecan-based chemo-therapy or prolonged infusion of 5-fluorouracil / folinic acid and oxaliplatin as first line of therapy; as monotherapy in the case of ineffectiveness of fluorouracil / folinic acid and oxaliplatin as first line of therapy; as monotherapy in the case of ineffectiveness of irinotecan. As well as intolerance to irinotecan. The inclusion of cetuximab in the treatment regimen increases the resectability of primary nonresectable metastases in the liver, as well as survival without progression in both operated patients and in inoperable cases. Patients with a common disease, metastases that can not become operable, need to prolong their life as much as possible, maintaining its acceptable quality, preventing or reducing the manifestation associated with the tumor of the symptoms. Cetuximab in combination with FOLFOX and FOLFIRI regimens increases the response to treatment, progression-free survival. The use of cetuximab in the second and third line of therapy increases the objective effect and overall survival.

The major side effects of cetuximab are skin reactions. Their presence, according to most studies, is a factor that correlates with the effectiveness of treatment with the inclusion of cetuximab. Thus, a meta-analysis of 13 clinical trials has shown that skin rashes caused by cetuximab are associated with a significant improvement in overall survival, progression-free survival and overall response rates [31].

Data from another meta-analysis, which included 38 studies, indicate that cetuximab and panitumumab chemotherapy has different toxicity profiles in terms of the frequency of severe side effects. Cetuximab was associated with lower skin toxicity, acne and paronychia were more commonly observed, but fewer cases of skin cracks and itching than when using panitumumab [32].

Although numerous placebo-controlled studies of cetuximab are an important indication of its efficacy, there is a higher degree of evidence of its clinical benefits. A recognized standard of evidence-based medicine is a meta-analysis of the results of numerous studies.

A meta-analysis of 5 comparative studies of the efficacy of the VEGF inhibitor (bevacizumab) with EGFR inhibitors (cetuximab or panitumumab) has been conducted with metastatic CRC wild-type RAS. The advantage of EGFR-inhibitor therapy compared with VEGF inhibitors relative to overall survival was found [33].

Meta-analysis of 10 studies was of interest that evaluates the prognostic role of primary tumor localization in metastatic CRC in patients receiving cetuximab. The authors conclude that in patients with left-sided CRC the prognosis is better than in patients with right-sided illnesses when treating cetuximab [34].

An updated systematic meta-analysis of 5 studies (1,464 patients) was performed to determine the efficacy of cetuximab plus FOLFIRI or FOLFOX as the first line of treatment for metastatic CRC in wild type KRAS patients. It has been found that the use of cetuximab is a potentially effective approach to improving the results. However, it has reported 3rd and 4th grade adverse effects in the group of wild-type KRAS patients, namely neutropenia and diarrhea. There was a higher incidence of diarrhea of 3 or 4 degrees for cetuximab plus Folfiri, no significant difference with respect to neutropenia was detected. The drug is considered relatively safe [35].

The data of the research carried out by other authors confirmed not only the efficacy, but also the relative safety of cetuximab in different subgroups and populations of patients and led to the approval of its use in the treatment of metastatic CRC.
Systematized data on the effect of cetuximab on increasing the life expectancy of cancer patients

| Study                                | Effect of cetuximab on survival rates |
|--------------------------------------|---------------------------------------|
| Randomized study EPIC (1 298 patients) | The combination of cetuximab + irinotecan significantly increased survival to progression (4.0 months versus 2.6 months (only with irinotecan application), respectively) [9]. |
| Randomized study CRYSTAL (1 217 patients) | The combination of cetuximab with FOLFIRI (irinotecan, 5-fluorouracil/5-fluorouracil) significantly increased the efficacy of treatment from 38.7 to 46.9 % and median survival without progression from 8.0 to 8.9 months, reducing the risk of progression of the tumor process to 15 %. The tolerability of the combination of FOLFIRI + cetuximab was satisfactory [10]. |
| Randomized study (1 198 patients) | Cetuximab has shown efficacy in combination with FOLFIRI in tumors with the wild KRAS gene. Indicators of survival without progression (median 909 months versus 8104 months, respectively) and overall survival (median 2305 months versus 2000 months) were significantly higher in the cetuximab group [11]. |
| Multicenter study BOND (329 patients) | Median survival without progression and overall survival was for the group cetuximab + irinotecan 4.1 and 8.6 months for the group cetuximab in mono-regime – 1.5 and 6.9 months [12]. |
| Randomized study AIO CRC_group (177 patients) | The efficacy and safety of XELOX regimens (capecitabine and oxaliplatin) and XELIRI (capecitabine and irinotecan) in combination with cetuximab in the I line of treatment in patients with metastatic CRC have been identified [13]. |
| Randomized study COIN-B (169 patients) | It has compared to 2 regimens for cetuximab and chemotherapy: after 12 weeks of treatment with “FOLFOX (oxalipatin, 5-fluorouracil, folic acid) + cetuximab weekly”, treatment interrupted or preserved cetuximab, then “FOLFOX + cetuximab” was repeated with similar follow-up treatment. Progression-free mediums were 12.0 and 13.7 months for the discontinuation and continued therapy with cetuximab, respectively. In the ongoing cetuximab group, the survival rate exceeded that in the intermittent treatment group (18.4 versus 20.1 months, respectively) [14]. |
| Randomized controlled study (138 patients) | In a study on the use of cetuximab in combination with chemotherapy compared with chemotherapy in patients with unresectable metastases in the liver, patients with cetuximab exhibited higher three-year survival (41 % vs. 18 %) and median overall survival (30.9 versus 21.0 months) [15]. |
| Randomized study (40 patients) | It has evaluated the efficacy of a two-week treatment with cetuximab and irinotecan as the third line for CRC patients. Median survival without progression, overall survival were 5.7 and 15.1 months [16]. |
| Randomized study (289 patients) | With the use of cetuximab as the first line of therapy in patients with CRC wild type KRAS, survival without progression and overall survival were 11.1 and 26.8 months [17]. |
| Randomized study (40 patients) | Combination therapy: cetuximab, irinotecan, oxaliplatin, capecitabine, of wild-type CRC patients are associated with a high level of response: mean survival without overall progression and overall survival were 17.8 and 62.5 months respectively [18]. |
| Randomized study (188 patients) | In patients with RAS and BRAF mutant tumors, the overall response rate was higher in the cetuximab group compared to bevacizumab (52 % vs. 40 %), but comparative results were obtained for progression-free survival [19]. |
| Randomized study (52 patients) | The polymorphisms of VKORC1, NAT2, ABCB1 genes are related to the efficacy of irinotecan, oxaliplatin, 5-fluorouracil and cetuximab in patients with CRC, with the highest survival rate of 4 years [20]. |
| Randomized study (54 patients) | In patients with refractory metastatic BRAF mutant CRC, the combination of cetuximab and enocarpenib has showed promising clinical activity and tolerability. Median survival without progression were 3.7 and 4.2 months for dual and triple therapy groups [21]. |
| Randomized study (110 patients) | The use of cetuximab as the first line of therapy in combination with oxaliplatin in patients with left-sided wild-type CRC is largely due to longer overall survival (36.2 versus 12.6 months) and survival without progression (11.1 versus 5.6 months) than the right-sided wild-type CRC [22]. |
| Randomized study (153 patients) | It has estimated the efficacy of cetuximab plus Folfox as the second-line therapy of CRC wild type KRAS. Survival without progression was in the Folfox group plus cetuximab 6.9 months against 5.3 months in the Folfox group. The median of overall survival; 23.7 versus 19.8 months, respectively [23]. |
| Randomized study (29 patients) | It has shown the effectiveness of cetuximab in patients with CRC with chemorrefractory codon KRAS G13D. The median overall survival was 8.0 months in the cetuximab group and 7.6 months in the group - cetuximab plus irinotecan [24]. |
| 1 | 2 |
|---|---|
| Randomized study (400 patients) | In patients with CRC wild type RAS, the average overall survival rate was higher in the Folfiri plus cetuximab group than in the Folfiri plus bevacizumab group (33.1 months versus 25.0 months), progression-free survival was comparable between groups [25]. |
| Randomized study (293 patients) | It has demonstrated the high efficacy of cetuximab in patients with CRC wild-type KRAS with FCGR2A H/H genotypes: the benefits of overall survival were 5.5 months [26]. |
| Randomized study (40 patients) | When using cetuximab in combination with XELOX in wild-type CRC patient’s survival without progression and overall survival were 6.5 and 24.3 months [27]. |
| Non-randomized study (37 patients) | When using cetuximab in combination therapy of the third line in wild-type CRC patient’s survival without progression and overall survival were 5.5 and 13.5 months [28]. |
| Randomized study (34 patients) | The efficacy and good tolerability of cetuximab in combination with irinotecan in Japanese patients with CRC wild-type KRAS have been shown. Survival without progression was 6 months; overall survival was 12.9 months [29]. |
| Randomized study (56 patients) | Median survival without progression in patients with unresectable metastases in the liver on treatment of Folfox and cetuximab was 10.8 months, Folfox and cetuximab – 10.5 months [30]. |

There is an analysis of economic efficiency using FIRE-3 clinical data to predict survival and life expectancy of FOLFIRI plus cetuximab or bevacizumab regimens as the first line of the metastatic CRC wild-type RAS treatment. Compared with bevacizumab, KRAS wild type patients receiving first-line cetuximab gained 5.7 months of life at a cost of $46266, for an incremental cost-effectiveness ratios of $97223/ per life year ($122610/ quality-adjusted life year). For extended RAS wild type patients, the incremental cost-effectiveness ratios was $77339/ per life year ($99584/ quality-adjusted life year). Treatment with cetuximab was cost-effective in 80.3 % of cases, given the willingness to pay $ 150000 per year. The analysis shows that treatment with cetuximab and FOLFIRI in patients with metastatic CRC wild type RAS improves clinical outcomes and uses financial resources more effectively than bevacizumab and FOLFIRI [36].

The large evidence base obtained in the course of numerical clinical studies suggests additional benefits, high efficacy, acceptable cetuximab safety and lower cost of treatment compared to other drugs. It should be noted that the production of cetuximab biosimilars will reduce the cost of treatment and improve access to CRC therapy.

7. Conclusions from the conducted research and prospects for further development of this field

1. Conducted analysis of clinical data suggests additional utility, high efficacy of cetuximab in the treatment of patients with metastatic CRC RAS wild type compared to other drugs. Cetuximab exhibits a synergistic effect with a number of cytostatic drugs, and also increases the effect of radiotherapy, with no increased toxic reactions when co-administered. The drug is considered relatively safe.

2. The use of cetuximab in patients with CRC is accompanied by a lower economic burden on the budget of drug provision for cancer patients than bevacizumab.

3. It has been shown that cetuximab is not only a clinically effective and relatively safe drug for the treatment of CRF, but also demonstrates its cost-effectiveness and additional benefits compared to other drugs, including bevacizumab.

References

1. Cancer prevention and control through an integrated approach. Geneva: World Health Organization, 2017. URL: http://apps.who.int/gb/ebwha/pdf_files/WHA70-REC1/A70_2017_REC1-en.pdf
2. Celis J. E., Pavalkis D. A mission-oriented approach to cancer in Europe: a joint mission/vision 2030 // Molecular Oncology. 2017. Vol. 11, Issue 12. P. 1661–1672. doi: http://doi.org/10.1002/1878-0261.12143
3. Mach J. P. Recombinant monoclonal antibodies, from tumor targeting to cancer immunotherapy, a critical overview // Molecular biology. 2017. Vol. 51, Issue 6. P. 1024–1038. doi: http://doi.org/10.7868/s0026898417060131
4. Kelly R. J., Smith T. J. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care // The Lancet Oncology. 2014. Vol. 15, Issue 3. P. e112–e118. doi: http://doi.org/10.1016/s1470-2045(13)70578-3
5. New treatments for advanced cancer: an approach to prioritization / Ferguson J. S., J., Summerhayes M., Masters S., Schey S., Smith I. E. // British Journal of Cancer. 2000. Vol. 83, Issue 10. P. 1268–1273. doi: http://doi.org/10.1054/bjoc.2000.1406
6. Collins M., Latimer N. NICE’s end of life decision making scheme: impact on population health // BMJ. 2013. Vol. 346, Issue 1. P. 1363–1363. doi: http://doi.org/10.1136/bmj.f1363
7. Dilts D.M. Time Has Come to Raise the Bar in Oncology Clinical Trials // Journal of Clinical Oncology. 2014. Vol. 32, Issue 12. P. 1186–1187. doi: http://doi.org/10.1200/jco.2013.54.5277
8. Polyakovka D. Half of the new drugs does not carry additional benefits // Weekly Pharmacy. 2019. Vol. 1174, Issue 3. URL: https://www.apteka.ua/article/487540
9. EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer / Sobrero A. F., Maurel J., Fehrenbacher L., Scheithauer W., Abubakr Y. A., Lutz M. P. et. al. // Journal of
Clinical Oncology. 2008. Vol. 26, Issue 14. P. 2311–2319. doi: http://doi.org/10.1200/jco.2007.13.1193

10. Randomized phase III study of irinotecan and SFUFA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer. CRISTAL trial / Cutsem E. Van, Nowacki M., Lang I., Cascini S., Shchepotin I. et. al. // Journal of Clinical Oncology. 2007. Vol. 25, Issue 18. P. 164.

11. Cetuximab Plus Irinotecan, Fluouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status / Van Cutsem E., Köhne C.-H., Láng L., Folprecht G., Nowacki M. P., Cascini S. et. al. // Journal of Clinical Oncology. 2011. Vol. 29, Issue 15. P. 2011–2019. doi: http://doi.org/10.1200/jco.2010.33.5091

12. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer / Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A. et. al. // New England Journal of Medicine. 2004. Vol. 351, Issue 4. P. 337–345. doi: http://doi.org/10.1056/nejmoa033025

13. Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group / Heinemann V., von Weikersthal L. F., Vehling-Kaiser U., Stauch M., Oruzu D., Schulze M. et. al. // Journal of Clinical Oncology. 2008. Vol. 26, Issue 15. P. 4033–4033. doi: http://doi.org/10.1200/jco.2008.39.15_suppl.4033

14. Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): Results of the two-arm phase II randomized MRC Coin-B trial. / Wasan H., Adams R. A., Wilson R. H., Pugh C., Fisher D., Madi A. et. al. // Journal of Clinical Oncology. 2012. Vol. 30, Issue 4. P. 536–536. doi: http://doi.org/10.1200/jco.2012.30.4_suppl.536

15. Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients WithKRASWild-Type Unresectable Rectal Liver-Limited Metastases / Ye L.-C., Liu T.-S., Ren L., Wei Y., Zhu D.-X., Zai S.-Y. et. al. // Journal of Clinical Oncology. 2013. Vol. 31, Issue 16. P. 1931–1938. doi: http://doi.org/10.1200/jco.2012.44.8308

16. Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer / Oumi H., Shinozaki E., Mashima T., Wakatsuki T., Suenaga M., Ichimura T. et. al. // Cancer Science. 2018. Vol. 109, Issue 8. P. 2567–2575. doi: http://doi.org/10.1111/cas.13698

17. Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study / Cheng A.-L., Cornelio G., Shen L., Price T., Yang T.-S., Chung I. J. et. al. // Clinical Colorectal Cancer. 2017. Vol. 16, Issue 2. P. 73–88. doi: http://doi.org/10.1016/j.cclc.2016.08.005

18. Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases / Pietrantonio F., Di Bartolomeo M., Cotsoglou C., Mennitto A., Berenato R., Morano F. et. al. // Clinical Colorectal Cancer. 2017. Vol. 16, Issue 3. P. 191–198. doi: http://doi.org/10.1016/j.cjc.2016.09.007

19. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevazumab: analysis of the FIRE-3 (AIO KRK-0306) study / Stintzing S., Miller-Phillips L., Modest D. P., Fischer von Weikersthal L., Decker T., Kiani A. et. al. // European Journal of Cancer. 2017. Vol. 79, P. 50–60. doi: http://doi.org/10.1016/j.ejca.2017.03.023

20. Randomized phase III study of bevacizumab in colorectal cancer / Van Geel R. M. J. M., Tabernero J., Elez E., Bendell J. C., Sprefaico A., Schuler M. et. al. // Cancer Discovery. 2017. Vol. 7, Issue 6. P. 610–619. doi: http://doi.org/10.1158/2159-8290.cd-16-0795

21. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer / Van Geel R. M. J. M., Tabernero J., Elez E., Bendell J. C., Sprefaico A., Schuler M. et. al. // Cancer Discovery. 2017. Vol. 7, Issue 6. P. 610–619. doi: http://doi.org/10.1158/2159-8290.cd-16-0795

22. Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials / Sunakawa Y., Ichikawa W., Tsuji A., Denda T., Segawa Y., Negoro Y. et. al. // Clinical Colorectal Cancer. 2017. Vol. 16, Issue 3. P. e171–e180. doi: http://doi.org/10.1016/j.cclc.2016.09.010

23. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX / Ciardiello F., Normanno N., Martinelli E., Troiani T., Pisconti S., Cardone C. et. al. // Annals of Oncology. 2016. Vol. 27, Issue 6. P. 1055–1061. doi: http://doi.org/10.1093/annonc/mdw136

24. Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study) / Nakamura M., Anyama T., Ishishaki K., Tsuji A., Takinishi Y., Shindo Y. // Cancer Chemotherapy and Pharmacology. 2016. Vol. 79, Issue 1. P. 29–36. doi: http://doi.org/10.1007/s00280-016-3203-7

25. FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus Bevacizumab for Metastatic Colorectal Cancer (FIRE-3): A phase III randomised trial / Stintzing S., Modest D. P., Rossius L., Lorch M. M., von Weikersthal L. F., Decker T. et. al. // The Lancet Oncology. 2016. Vol. 17, Issue 10. P. 1426–1434. doi: http://doi.org/10.1016/S1470-2045(16)30269-8

26. Fc- Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer / Liu G., Tu D., Lewis M., Cheng D., Sullivan L. A., Chen Z. et. al. // Clinical Cancer Research. 2016. Vol. 22, Issue 10. P. 2435–2444. doi: http://doi.org/10.1158/1078-0432.ccr-15-0414

27. A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study) / Hazama S., Maeda H., Iwamoto S., Kim H. M., Takemoto H., Kobayashi K. et. al. // Clinical Colorectal Cancer. 2016. Vol. 15, Issue 4. P. 329–336. doi: http://doi.org/10.1016/j.cjc.2016.07.003

28. Multicenter phase II study of administration of cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study) / Takahashi T.,
29. Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients / Terazawa T., Nishitani H., Kato K., Hashimoto H., Akiyoshi, K., Ito Y. // Asia-Pacific Journal of Clinical Oncology. 2015. Vol. 13, Issue 2. P. e132–e137. doi: http://doi.org/10.1111/ajco.12405

30. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study) / Folprecht G., Gruenberger T., Bechstein W., Raab H.-R., Weitz J., Lordick F. et. al. // Annals of Oncology. 2014. Vol. 25, Issue 5. P. 1018–1025. doi: http://doi.org/10.1093/annonc/mdu088

31. Abdel-Rahman O., Fouad M. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: A systematic review and meta-analysis // Critical Reviews in Oncology/Hematology. 2015. Vol. 93, Issue 2. P. 127–135. doi: http://doi.org/10.1016/j.critrevonc.2014.07.005

32. Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis / Petrelli F., Ardito R., Ghidini A., Zaniboni A., Ghidini M., Barni S., Tomasello G. // Oncology. 2018. Vol. 94, Issue 4. P. 191–199. doi: http://doi.org/10.1159/000486338

33. Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type RAS metastatic colorectal cancer: a meta-analysis / Jiang W., Yu Q., Ning R., Zhao W., Wei C. // Oncotargets and Therapy. 2018. Vol. 11. P. 4271–4281. doi: http://doi.org/10.2147/ott.s168695

34. The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis / Cao D.-D., Xu H.-L., Xu X.-M., Ge W. // Oncotarget. 2017. Vol. 8, Issue 32. P. 53631–53641. doi: http://doi.org/10.18632/oncotarget.19022

35. Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FOFIRI+cetuximab as the first-line treatment for metastatic colorectal cancer / Yang Y.-F., Wang G.-Y., He J.-L., Wu F.-P., Zhang Y.-N. // Medicine. 2017. Vol. 96, Issue 12. P. e6335. doi: http://doi.org/10.1097/md.0000000000006335

36. Shankaran, V., Ortedahl, J. D., Purdum, A. G., Bolinder, B., Anene, A. M., Sun, G. H., Bentley, T. G. K. (2015). Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States. American Journal of Clinical Oncology, 41 (1), 65–72. doi: http://doi.org/10.1097/coj.0000000000000231

Дата надходження рукопису 14.03.2019

Elena Litvinova, Doctor of Pharmaceutical Sciences, Associate Professor, Department of Management and Economics of Enterprise, National University of Pharmacy, Pushkinska str., 53, Kharkiv, Ukraine, 61002
E-mail: hlitvinova@gmail.com